Category: General Biotechnology

Biobetters, Supergenerics Hold Many Advantages for Pharma Companies

By Larry Ramer, DrugPatentWatch writer A growing number of pharmaceutical companies are looking to simultaneously benefit from the low costs of developing generic treatments and the increased market share and…
The post Biobetters, Supergenerics H…


Biotech in Countries Starting with “I” – Part 12: Israel

This is a guest post from Susan K Finston, President of Finston Consulting.  A little over five years ago I penned the first installment in this irregular series, focused on Israel’s tech transfer prowess and efforts to encourage innovative life-sciences. I tracked the Start-Up Nation’s incremental progress here.    In a nutshell, Israel leveraged excellence in basic science and […]


Factors driving healthcare costs in the US

Health care costs in the US touched a staggering $3.2 trillion in 2015, which makes it one of the nation’s largest industries, equaling 17.8% of gross domestic product. This translates…
The post Factors driving healthcare costs in the US appeared…


Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients

Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications Driven by patient loyalty, prescriber preference, pharmacist trust, and traditional marketing, branded generics&#…


Formulary Decisions: Exploring the Ethics of Drug Approval

Formularies come into effect at the hospital level and the individual insurer level When developed and managed with due care and consideration, drug formularies can be a good tool for…
The post Formulary Decisions: Exploring the Ethics of Drug Ap…


Top 6 issues facing the biotechnology industry

For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while it didn’t for the rest. In some cases, we knew…
The post Top 6 issues facing the biotechnology industry appea…


Tracking 20 Years of Compound-to-Target Output from Literature and Patents

This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…


Do Patents Drive or Hinder Innovation?

Here’s a brief note in response to some of the discussions I’ve seen regarding the merit of patents. Many of the anti-patent arguments focus on things which probably never should have been patented. But few address the things which only exist because of patents. In some industries (e.g. software), patents are often seen as a […]


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: